HRGN Stock Overview
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, engages in developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma, or birth defects.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Harvard Apparatus Regenerative Technology Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.00 |
52 Week High | US$6.48 |
52 Week Low | US$2.13 |
Beta | -1.48 |
1 Month Change | -21.05% |
3 Month Change | -39.64% |
1 Year Change | -49.49% |
3 Year Change | 118.18% |
5 Year Change | 37.61% |
Change since IPO | -97.50% |
Recent News & Updates
Recent updates
Shareholder Returns
HRGN | US Biotechs | US Market | |
---|---|---|---|
7D | -4.8% | -0.5% | 0.6% |
1Y | -49.5% | 9.6% | 29.5% |
Return vs Industry: HRGN underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: HRGN underperformed the US Market which returned 29.8% over the past year.
Price Volatility
HRGN volatility | |
---|---|
HRGN Average Weekly Movement | 19.0% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HRGN's share price has been volatile over the past 3 months.
Volatility Over Time: HRGN's weekly volatility has increased from 14% to 19% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 8 | Jerry He | https://www.hregen.com |
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, engages in developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma, or birth defects. The company’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease.
Harvard Apparatus Regenerative Technology Inc. Fundamentals Summary
HRGN fundamental statistics | |
---|---|
Market cap | US$40.92m |
Earnings (TTM) | -US$8.60m |
Revenue (TTM) | US$40.00k |
1,046x
P/S Ratio-4.9x
P/E RatioIs HRGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HRGN income statement (TTM) | |
---|---|
Revenue | US$40.00k |
Cost of Revenue | US$13.00k |
Gross Profit | US$27.00k |
Other Expenses | US$8.62m |
Earnings | -US$8.60m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.62 |
Gross Margin | 67.50% |
Net Profit Margin | -21,490.45% |
Debt/Equity Ratio | 0% |
How did HRGN perform over the long term?
See historical performance and comparison